ATE439866T1 - Kontrastmittel für die magnetresonanzbildgebung mit cest-aktivem paramagnetischem komplex - Google Patents

Kontrastmittel für die magnetresonanzbildgebung mit cest-aktivem paramagnetischem komplex

Info

Publication number
ATE439866T1
ATE439866T1 AT06727994T AT06727994T ATE439866T1 AT E439866 T1 ATE439866 T1 AT E439866T1 AT 06727994 T AT06727994 T AT 06727994T AT 06727994 T AT06727994 T AT 06727994T AT E439866 T1 ATE439866 T1 AT E439866T1
Authority
AT
Austria
Prior art keywords
cest
contrast agents
magnetic resonance
resonance imaging
paramagnetic complex
Prior art date
Application number
AT06727994T
Other languages
English (en)
Inventor
Nicolaas Willard
Rene Wegh
Jeroen Pikkemaat
Holger Gruell
Original Assignee
Koninkl Philips Electronics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninkl Philips Electronics Nv filed Critical Koninkl Philips Electronics Nv
Application granted granted Critical
Publication of ATE439866T1 publication Critical patent/ATE439866T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicinal Preparation (AREA)
AT06727994T 2005-04-26 2006-04-21 Kontrastmittel für die magnetresonanzbildgebung mit cest-aktivem paramagnetischem komplex ATE439866T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05103356 2005-04-26
PCT/IB2006/051235 WO2006114738A2 (en) 2005-04-26 2006-04-21 Mri contrast agents comprising cest active paramagnetic complex

Publications (1)

Publication Number Publication Date
ATE439866T1 true ATE439866T1 (de) 2009-09-15

Family

ID=37215130

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06727994T ATE439866T1 (de) 2005-04-26 2006-04-21 Kontrastmittel für die magnetresonanzbildgebung mit cest-aktivem paramagnetischem komplex

Country Status (7)

Country Link
US (1) US8734761B2 (de)
EP (1) EP1881852B1 (de)
JP (1) JP5638752B2 (de)
CN (1) CN101166547B (de)
AT (1) ATE439866T1 (de)
DE (1) DE602006008604D1 (de)
WO (1) WO2006114738A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292354A1 (en) * 2004-09-23 2007-12-20 Guerbet Contrast Agents Encapsulating Systems for Cest Imaging
CN101166988B (zh) * 2005-04-26 2012-06-13 皇家飞利浦电子股份有限公司 改进对mri对比增强的检测的方法和设备
EP2065058A1 (de) * 2007-11-28 2009-06-03 Koninklijke Philips Electronics N.V. Nicht kugelförmige Kontrastmittel für CEST-MRI auf der Basis des magnetischen Bulk-Suszeptibilitätseffekts
US9815712B2 (en) 2008-10-03 2017-11-14 California Institute Of Technology High capacity perchlorate-selective resins from hyperbranched macromolecules
WO2010040117A2 (en) 2008-10-03 2010-04-08 California Institute Of Technology Extraction of anions from solutions and mixtures using hyperbranched macromolecules
US8658702B2 (en) 2009-12-17 2014-02-25 Mamadou Diallo Soluble anion exchangers from hyperbranched macromolecules
WO2012024396A2 (en) * 2010-08-17 2012-02-23 Rutgers, The State University Of New Jersey Compositions and methods for delivering nucleic acid molecules and treating cancer
WO2012070681A1 (ja) * 2010-11-26 2012-05-31 国立大学法人九州大学 常磁性を有する水溶性ハイパーブランチポリマー
JP6092121B2 (ja) * 2011-01-09 2017-03-08 エイエヌピー テクノロジーズ， インコーポレイテッド 疎水性分子に誘起された分岐ポリマー凝集体及びその使用
US9604213B2 (en) 2012-02-13 2017-03-28 Neumodx Molecular, Inc. System and method for processing and detecting nucleic acids
US9738887B2 (en) 2012-02-13 2017-08-22 Neumodx Molecular, Inc. Microfluidic cartridge for processing and detecting nucleic acids
US11485968B2 (en) 2012-02-13 2022-11-01 Neumodx Molecular, Inc. Microfluidic cartridge for processing and detecting nucleic acids
US11648561B2 (en) 2012-02-13 2023-05-16 Neumodx Molecular, Inc. System and method for processing and detecting nucleic acids
US9637775B2 (en) 2012-02-13 2017-05-02 Neumodx Molecular, Inc. System and method for processing biological samples
WO2014066376A1 (en) * 2012-10-25 2014-05-01 Neumodx Molecular, Inc. Method and materials for isolation of nucleic acid materials
JP6297440B2 (ja) * 2013-07-31 2018-03-20 キヤノンメディカルシステムズ株式会社 造影剤
JP6411117B2 (ja) 2013-07-31 2018-10-24 キヤノンメディカルシステムズ株式会社 医用画像診断装置及び超音波診断装置
CN104623697B (zh) * 2015-02-08 2017-03-22 中国科学院武汉物理与数学研究所 一种基于人体生理温度响应的聚合物胶束型磁共振造影剂的制备方法
US9890187B2 (en) 2015-06-26 2018-02-13 Epos-Iasis Research And Development, Ltd. Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
EP3394627B1 (de) * 2015-12-23 2020-06-03 Bracco Imaging S.p.A Ratiometrisch gepulste cest-bildgebung
WO2017147418A1 (en) 2016-02-24 2017-08-31 Ohio State Innovation Foundation Methods and devices for contrast agent magnetic resonance imaging
CN105963718A (zh) * 2016-04-28 2016-09-28 东华大学 一种麦芽糖修饰的钆基螯合物mr造影剂的制备方法
WO2018053460A1 (en) * 2016-09-19 2018-03-22 The Regents Of The University Of California Paramagnetic polymers
ES2814555T3 (es) * 2016-11-28 2021-03-29 Bayer Pharma AG Compuestos de quelato de gadolinio con alta relaxividad para usar en la obtención de imágenes por resonancia magnética
CN108743977B (zh) * 2018-04-03 2021-03-02 中国科学院武汉物理与数学研究所 一种无重金属离子卟啉化合物造影剂及其在磁共振成像中的应用
WO2019240884A2 (en) 2018-04-27 2019-12-19 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
CN120609858A (zh) * 2025-05-30 2025-09-09 中国科学院精密测量科学与技术创新研究院 镧系金属配合物作为31p cest高场造影剂在识别atp中的应用
CN120668710A (zh) * 2025-05-30 2025-09-19 中国科学院精密测量科学与技术创新研究院 一种基于高场（≥5.0t）31p cest的磷酸根识别方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US19878A (en) * 1858-04-06 Improvement in plows
US5914095A (en) * 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
US6693190B1 (en) * 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
US6746662B1 (en) * 1999-02-09 2004-06-08 Board Of Regents The University Of Texas System pH sensitive MRI contrast agents
WO2000047111A1 (en) 1999-02-09 2000-08-17 Board Of Regents The University Of Texas System Ph sensitive mri contrast agents
US6963769B1 (en) 1999-04-21 2005-11-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for enhancing contrast produced by MRI
JP2004510830A (ja) * 2000-10-11 2004-04-08 ターゲサム・インコーポレーテッド 標的化された治療用薬剤
WO2002043775A2 (en) 2000-11-20 2002-06-06 GODFREY, Cullen, M. Paramagnetic metal ion-based macrocyclic contrast agents
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
DE10135355C1 (de) * 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
AU2002364728A1 (en) * 2001-12-13 2003-06-23 The Johns Hopkins University School Of Medicine Method for mr/nmr imaging
EP1331012A1 (de) 2002-01-29 2003-07-30 BRACCO IMAGING S.p.A. Magnetisch beeinflussbare paramagnetische Kontrastmittel für Magnetresonanzbildgebung
JP4355144B2 (ja) 2003-01-21 2009-10-28 学校法人日本大学 新規含窒素環状化合物
EP1466629A1 (de) 2003-04-11 2004-10-13 BRACCO IMAGING S.p.A. Adducte zwischen NMR Vershibungsreagenzen und Substraten mit austauschbaren Protonen für die "CEST" Anwendung
US20040258614A1 (en) * 2003-06-20 2004-12-23 University Of Maryland, Baltimore Microparticles for microarterial imaging and radiotherapy
US20070292354A1 (en) * 2004-09-23 2007-12-20 Guerbet Contrast Agents Encapsulating Systems for Cest Imaging

Also Published As

Publication number Publication date
WO2006114738A3 (en) 2007-06-21
CN101166547A (zh) 2008-04-23
WO2006114738A2 (en) 2006-11-02
EP1881852A2 (de) 2008-01-30
JP2008539223A (ja) 2008-11-13
JP5638752B2 (ja) 2014-12-10
US20080193384A1 (en) 2008-08-14
DE602006008604D1 (de) 2009-10-01
CN101166547B (zh) 2013-02-06
EP1881852B1 (de) 2009-08-19
US8734761B2 (en) 2014-05-27

Similar Documents

Publication Publication Date Title
ATE439866T1 (de) Kontrastmittel für die magnetresonanzbildgebung mit cest-aktivem paramagnetischem komplex
Maffei Magnetic fields and cancer: epidemiology, cellular biology, and theranostics
Gallagher et al. Production of hyperpolarized [1, 4-13C2] malate from [1, 4-13C2] fumarate is a marker of cell necrosis and treatment response in tumors
Sharma et al. MRI‐based quantitative susceptibility mapping (QSM) and R2* mapping of liver iron overload: Comparison with SQUID‐based biomagnetic liver susceptometry
Singh et al. On B1 inhomogeneity correction of in vivo human brain glutamate chemical exchange saturation transfer contrast at 7T
Kim et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck
Cai et al. Creatine CEST MRI for differentiating gliomas with different degrees of aggressiveness
Marco‐Rius et al. Hyperpolarized singlet lifetimes of pyruvate in human blood and in the mouse
SE9903185D0 (sv) Terapeutisk metod och anordning baserad på magnetism
Albatany et al. Dichloroacetate induced intracellular acidification in glioblastoma: in vivo detection using AACID-CEST MRI at 9.4 Tesla
ATE519110T1 (de) Diagnostischer nanosensor und dessen verwendung in der medizin
DK1469890T3 (da) Reaktivt paramagnetisk kontrastmiddel til magnetresonansbilledteknik
Zhou et al. Glutamate-weighted chemical exchange saturation transfer magnetic resonance imaging detects glutaminase inhibition in a mouse model of triple-negative breast cancer
Corrado et al. Ovarian metastasis from thyroid carcinoma: a case report and literature review
Tain et al. Improving the detection specificity of endogenous MRI for reactive oxygen species (ROS)
Liu et al. MagA expression attenuates iron export activity in undifferentiated multipotent P19 cells
Cai et al. Characterizing prostate tumor mouse xenografts with CEST and MT-MRI and redox scanning
Panebianco et al. Role of magnetic resonance spectroscopic imaging ([1H] MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA)
Donnelly et al. Bacterial association with metals enables in vivo monitoring of urogenital microbiota using magnetic resonance imaging
WO2014165719A1 (en) Non-invasive imaging of tissue redox state by mri
Yu et al. Non‐invasive physiology and pharmacology using 19F magnetic resonance
Wang et al. [Retracted] Angiopep‐2 as an Exogenous Chemical Exchange Saturation Transfer Contrast Agent in Diagnosis of Alzheimer’s Disease
GB0517077D0 (en) Imaging agent
Vinogradov MRI monitoring of energy storage in vivo using magnetization pathways
Rami et al. Carbonic anhydrase inhibitors: Gd (III) complexes of DOTA-and TETA-sulfonamide conjugates targeting the tumor associated carbonic anhydrase isozymes IX and XII

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties